The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter 
Professionals >> Visit The Body PROThe Body en Espanol
Ask the Experts About

Choosing Your MedsChoosing Your Meds
Rollover images to visit our other forums!
  • Email Email
  • Glossary Glossary

Is this PEP regimen OK?
Oct 2, 2009

After a recent potential exposure I was prescribed Truvada one tablet daily for 20 days and Kaletra two tablets daily for 10 days. So both medications had a dispense/supply of 20 tablets each.

This is kind of an unusual regimen that I have seen unlike in this forum where I heard of one medication like either combivir or truvada daily for 28 days (so 28 tabs in total). But this was presribed at the Northwestern University medical centre in Chicago which is among the best in the country so I am assuming they know what they are doing. What is your opinion on this regimen? Many thanks for the help and support you provide to people here.

Response from Dr. Young

Hello and thanks for your post.

While many prescribe two NRTIs like Combivir or Truvada pills you've listed, if it were my exposure, I'd want a boosted protease inhibitor too. So, assuming that your exposure was a significant one (difficult to define sometimes), then I agree with the folks at Northwestern with the Truvada+Kaletra regimen they've given you.

Best of luck to you, BY

Mensturation and HIV

  • Email Email
  • Glossary Glossary



This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint